Arbutus Biopharma Cp (ABUS)

$3.06 -0.08 (-2.55%)
Market Cap 592.57M
Revenue (ttm) 18.14M
Net Income (ttm) -72.85M
EPS (ttm) N/A
PE Ratio N/A
Forward PE N/A
Profit Margin N/A
Debt to Equity Ratio N/A
Volume 649,900
Avg Vol 936,122
Day's Range N/A - N/A
Shares Out 188.72M
Stochastic %K 2%
Beta 1.98
Analysts Strong Sell
Price Target $4.50

Company Profile

Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 1 and phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the poten...

Industry: Biotechnology
Sector: Healthcare
Phone: 267 469 0914
Address:
701 Veterans Circle, Warminster, United States
Alfalcon
Alfalcon Mar. 15 at 8:44 PM
$ABUS
0 · Reply
Blueviking
Blueviking Mar. 15 at 6:51 PM
$ABUS Knock knock, Phizer…
0 · Reply
DocPharm
DocPharm Mar. 14 at 5:42 PM
$ABUS errr quite obvious they brought in the ex-AG Lindsay to assist with the layup on Moderna Hmmm what other linkages do these execs have
3 · Reply
DocPharm
DocPharm Mar. 14 at 5:38 PM
$ABUS
2 · Reply
DocPharm
DocPharm Mar. 14 at 5:35 PM
$ABUS hep b licensing ? buyback / divvy ? Pfizer /BTNX subsid? All valid Qs coming up
0 · Reply
Blueviking
Blueviking Mar. 14 at 2:31 PM
$ABUS Hold on tight! These guys know whats going on and will demand 5-10 x
1 · Reply
DivineCandles
DivineCandles Mar. 14 at 5:49 AM
$ABUS biotechnology company Arbutus Biopharma
0 · Reply
jim64
jim64 Mar. 13 at 7:39 PM
$ABUS This isn’t even close to being over… hang on and find out or stop crying and get out…you will be happy and so will we…good luck.
4 · Reply
Albert13906
Albert13906 Mar. 13 at 6:04 PM
$ABUS down to 3.15
0 · Reply
Onethousand1
Onethousand1 Mar. 13 at 5:58 PM
$ABUS any update on when 2025 earnings call? Surely they will give update on dividend etc.
3 · Reply
Latest News on ABUS
Moderna to Pay $950 Million to Settle Patent Cases From Arbutus, Genevant

Mar 3, 2026, 4:46 PM EST - 12 days ago

Moderna to Pay $950 Million to Settle Patent Cases From Arbutus, Genevant

MRNA

Moderna agrees to pay up to $2.25 billion to settle COVID vaccine patent dispute

Mar 3, 2026, 4:26 PM EST - 12 days ago

Moderna agrees to pay up to $2.25 billion to settle COVID vaccine patent dispute

MRNA ROIV

Roivant Announces Genevant Sciences' and Arbutus Biopharma's $2.25 Billion Global Settlement With Moderna

Mar 3, 2026, 4:15 PM EST - 12 days ago

Roivant Announces Genevant Sciences' and Arbutus Biopharma's $2.25 Billion Global Settlement With Moderna

ROIV MRNA

Genevant Sciences and Arbutus Biopharma Announce $2.25 Billion Global Settlement With Moderna

Mar 3, 2026, 4:15 PM EST - 12 days ago

Genevant Sciences and Arbutus Biopharma Announce $2.25 Billion Global Settlement With Moderna

ROIV MRNA

Moderna Resolves Global Patent Litigation with Arbutus/Genevant

Mar 3, 2026, 4:15 PM EST - 12 days ago

Moderna Resolves Global Patent Litigation with Arbutus/Genevant

MRNA

Arbutus Biopharma: LNP Litigation And Imdusiran Drive Near-Term Catalysts

Feb 3, 2026, 7:48 AM EST - 5 weeks ago

Arbutus Biopharma: LNP Litigation And Imdusiran Drive Near-Term Catalysts

Arbutus Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Nov 13, 2025, 7:30 AM EST - 4 months ago

Arbutus Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Arbutus Announces Four Abstracts Accepted for Presentation at AASLD - The Liver Meeting® 2025

Oct 7, 2025, 8:00 AM EDT - 5 months ago

Arbutus Announces Four Abstracts Accepted for Presentation at AASLD - The Liver Meeting® 2025

Arbutus Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 6, 2025, 7:30 AM EDT - 7 months ago

Arbutus Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Arbutus Reacquires Greater China Rights to Imdusiran and Announces Scientific Advisory Board with Late-Stage Clinical Focus

Jun 25, 2025, 7:30 AM EDT - 9 months ago

Arbutus Reacquires Greater China Rights to Imdusiran and Announces Scientific Advisory Board with Late-Stage Clinical Focus

Arbutus Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 14, 2025, 7:30 AM EDT - 10 months ago

Arbutus Reports First Quarter 2025 Financial Results and Provides Corporate Update

Arbutus Presents Clinical Trial Data from its Two HBV Assets, Imdusiran and AB-101, at the European Association for the Study of the Liver (EASL) Congress 2025

May 7, 2025, 2:01 AM EDT - 11 months ago

Arbutus Presents Clinical Trial Data from its Two HBV Assets, Imdusiran and AB-101, at the European Association for the Study of the Liver (EASL) Congress 2025

Arbutus to Present Imdusiran and AB-101 Data at EASL Congress 2025

Apr 23, 2025, 2:01 AM EDT - 11 months ago

Arbutus to Present Imdusiran and AB-101 Data at EASL Congress 2025

Arbutus Biopharma Cuts Workforce by More Than Half, Hires New CFO in Exec Shuffle

Mar 27, 2025, 7:56 AM EDT - 1 year ago

Arbutus Biopharma Cuts Workforce by More Than Half, Hires New CFO in Exec Shuffle

Arbutus Reports Fourth Quarter and Year End 2024 Financial Results and Provides Corporate Update

Mar 27, 2025, 7:30 AM EDT - 1 year ago

Arbutus Reports Fourth Quarter and Year End 2024 Financial Results and Provides Corporate Update

Genevant Sciences and Arbutus Biopharma Initiate International Patent Infringement Enforcement Actions Against Moderna

Mar 3, 2025, 9:15 AM EST - 1 year ago

Genevant Sciences and Arbutus Biopharma Initiate International Patent Infringement Enforcement Actions Against Moderna

ROIV

Arbutus Announces Changes to Board of Directors and Appointment of Lindsay Androski as CEO

Feb 25, 2025, 7:00 AM EST - 1 year ago

Arbutus Announces Changes to Board of Directors and Appointment of Lindsay Androski as CEO

Arbutus, Burford Capital, And Cadiz With Chris DeMuth Jr.

Jan 30, 2025, 3:40 PM EST - 1 year ago

Arbutus, Burford Capital, And Cadiz With Chris DeMuth Jr.

BUR CDZI

Arbutus Provides 2025 Corporate and Financial Update

Jan 13, 2025, 7:30 AM EST - 1 year ago

Arbutus Provides 2025 Corporate and Financial Update

Arbutus: Positive Imdusiran Data Leads To Phase 2B Development

Jan 7, 2025, 7:56 AM EST - 1 year ago

Arbutus: Positive Imdusiran Data Leads To Phase 2B Development

Whitefort Capital Sends Letter to Arbutus Biopharma Board of Directors

Dec 3, 2024, 8:00 AM EST - 1 year ago

Whitefort Capital Sends Letter to Arbutus Biopharma Board of Directors

Arbutus to Participate in H.C Wainwright @ Home Virtual Fireside Chat

Nov 26, 2024, 7:30 AM EST - 1 year ago

Arbutus to Participate in H.C Wainwright @ Home Virtual Fireside Chat

Arbutus' Imdusiran Achieves Functional Cure in cHBV Patients when Combined with a Short Course of Interferon

Nov 15, 2024, 11:02 AM EST - 1 year ago

Arbutus' Imdusiran Achieves Functional Cure in cHBV Patients when Combined with a Short Course of Interferon

Arbutus to Present at Jefferies London Healthcare Conference

Nov 14, 2024, 7:30 AM EST - 1 year ago

Arbutus to Present at Jefferies London Healthcare Conference

Arbutus Biopharma Corporation (ABUS) Q3 2024 Earnings Call Transcript

Nov 6, 2024, 2:52 PM EST - 1 year ago

Arbutus Biopharma Corporation (ABUS) Q3 2024 Earnings Call Transcript

Arbutus to Report Third Quarter 2024 Financial Results and Provide Corporate Update

Oct 23, 2024, 7:30 AM EDT - 1 year ago

Arbutus to Report Third Quarter 2024 Financial Results and Provide Corporate Update

Arbutus Announces Multiple Abstracts Highlighting Imdusiran Data Accepted for Presentation at AASLD - The Liver Meeting® 2024

Oct 15, 2024, 8:16 AM EDT - 1 year ago

Arbutus Announces Multiple Abstracts Highlighting Imdusiran Data Accepted for Presentation at AASLD - The Liver Meeting® 2024

Arbutus to Participate in Two Upcoming Investor Conferences

Sep 3, 2024, 7:30 AM EDT - 1 year ago

Arbutus to Participate in Two Upcoming Investor Conferences

Arbutus Biopharma Corporation (ABUS) Q2 2024 Earnings Call Transcript

Aug 1, 2024, 2:00 PM EDT - 1 year ago

Arbutus Biopharma Corporation (ABUS) Q2 2024 Earnings Call Transcript

Arbutus Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Aug 1, 2024, 7:30 AM EDT - 1 year ago

Arbutus Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Arbutus to Report Second Quarter 2024 Financial Results and Provide Corporate Update

Jul 18, 2024, 7:30 AM EDT - 1 year ago

Arbutus to Report Second Quarter 2024 Financial Results and Provide Corporate Update

Arbutus Biopharma's IP Legal Wins And Clinical Trials - A Strong Buy Opportunity

Jul 5, 2024, 5:29 AM EDT - 1 year ago

Arbutus Biopharma's IP Legal Wins And Clinical Trials - A Strong Buy Opportunity

Treatment with Arbutus' Imdusiran and VTP-300 Achieves Statistical Significance in Lowering HBsAg Levels

Jun 6, 2024, 11:15 AM EDT - 1 year ago

Treatment with Arbutus' Imdusiran and VTP-300 Achieves Statistical Significance in Lowering HBsAg Levels

Arbutus' Imdusiran with Short Course Interferon Achieves Sustained Undetectable HBsAg, a Necessity for HBV Functional Cure

Jun 5, 2024, 2:30 AM EDT - 1 year ago

Arbutus' Imdusiran with Short Course Interferon Achieves Sustained Undetectable HBsAg, a Necessity for HBV Functional Cure

Arbutus Distributors Ltd. News Release

Jun 3, 2024, 9:50 AM EDT - 1 year ago

Arbutus Distributors Ltd. News Release

Arbutus to Participate in Jefferies Global Healthcare Conference

May 29, 2024, 7:30 AM EDT - 1 year ago

Arbutus to Participate in Jefferies Global Healthcare Conference

Arbutus to Present Imdusiran Data at EASL Congress 2024

May 22, 2024, 2:00 AM EDT - 1 year ago

Arbutus to Present Imdusiran Data at EASL Congress 2024

Whitefort Capital Publishes Open Letter to Arbutus Biopharma Shareholders Outlining Paths to Maximize Value

May 17, 2024, 9:00 AM EDT - 1 year ago

Whitefort Capital Publishes Open Letter to Arbutus Biopharma Shareholders Outlining Paths to Maximize Value

Arbutus Biopharma Corporation (ABUS) Q1 2024 Earnings Call Transcript

May 2, 2024, 1:15 PM EDT - 2 years ago

Arbutus Biopharma Corporation (ABUS) Q1 2024 Earnings Call Transcript

Arbutus Reports First Quarter 2024 Financial Results and Provides Corporate Update

May 2, 2024, 7:30 AM EDT - 2 years ago

Arbutus Reports First Quarter 2024 Financial Results and Provides Corporate Update

Arbutus Announces Retirement of Chief Scientific Officer, Michael J. Sofia, PhD, Effective December 31, 2024

May 2, 2024, 7:25 AM EDT - 2 years ago

Arbutus Announces Retirement of Chief Scientific Officer, Michael J. Sofia, PhD, Effective December 31, 2024

Arbutus to Report First Quarter 2024 Financial Results and Provide Corporate Update

Apr 18, 2024, 7:30 AM EDT - 2 years ago

Arbutus to Report First Quarter 2024 Financial Results and Provide Corporate Update

Arbutus Biopharma Announces Claim Construction Ruling in its Ongoing Patent Infringement Lawsuit Against Moderna

Apr 4, 2024, 8:30 AM EDT - 2 years ago

Arbutus Biopharma Announces Claim Construction Ruling in its Ongoing Patent Infringement Lawsuit Against Moderna

Arbutus Biopharma Corporation (ABUS) Q4 2023 Earnings Call Transcript

Feb 29, 2024, 1:05 PM EST - 2 years ago

Arbutus Biopharma Corporation (ABUS) Q4 2023 Earnings Call Transcript

Arbutus Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate Update

Feb 29, 2024, 7:30 AM EST - 2 years ago

Arbutus Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate Update

Arbutus to Report Fourth Quarter and Year End 2023 Financial Results and Provide Corporate Update

Feb 15, 2024, 7:30 AM EST - 2 years ago

Arbutus to Report Fourth Quarter and Year End 2023 Financial Results and Provide Corporate Update

Arbutus Announces 2024 Corporate Objectives and Provides Financial Update

Jan 8, 2024, 7:30 AM EST - 2 years ago

Arbutus Announces 2024 Corporate Objectives and Provides Financial Update

Arbutus Biopharma and Barinthus Bio Present Preliminary Data from Phase 2a Clinical Trial Combining Imdusiran with VTP-300 at AASLD - The Liver Meeting®

Nov 9, 2023, 4:01 PM EST - 2 years ago

Arbutus Biopharma and Barinthus Bio Present Preliminary Data from Phase 2a Clinical Trial Combining Imdusiran with VTP-300 at AASLD - The Liver Meeting®

Arbutus Biopharma Corporation (ABUS) Q3 2023 Earnings Call Transcript

Nov 7, 2023, 11:06 AM EST - 2 years ago

Arbutus Biopharma Corporation (ABUS) Q3 2023 Earnings Call Transcript

Arbutus Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Nov 7, 2023, 7:30 AM EST - 2 years ago

Arbutus Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Alfalcon
Alfalcon Mar. 15 at 8:44 PM
$ABUS
0 · Reply
Blueviking
Blueviking Mar. 15 at 6:51 PM
$ABUS Knock knock, Phizer…
0 · Reply
DocPharm
DocPharm Mar. 14 at 5:42 PM
$ABUS errr quite obvious they brought in the ex-AG Lindsay to assist with the layup on Moderna Hmmm what other linkages do these execs have
3 · Reply
DocPharm
DocPharm Mar. 14 at 5:38 PM
$ABUS
2 · Reply
DocPharm
DocPharm Mar. 14 at 5:35 PM
$ABUS hep b licensing ? buyback / divvy ? Pfizer /BTNX subsid? All valid Qs coming up
0 · Reply
Blueviking
Blueviking Mar. 14 at 2:31 PM
$ABUS Hold on tight! These guys know whats going on and will demand 5-10 x
1 · Reply
DivineCandles
DivineCandles Mar. 14 at 5:49 AM
$ABUS biotechnology company Arbutus Biopharma
0 · Reply
jim64
jim64 Mar. 13 at 7:39 PM
$ABUS This isn’t even close to being over… hang on and find out or stop crying and get out…you will be happy and so will we…good luck.
4 · Reply
Albert13906
Albert13906 Mar. 13 at 6:04 PM
$ABUS down to 3.15
0 · Reply
Onethousand1
Onethousand1 Mar. 13 at 5:58 PM
$ABUS any update on when 2025 earnings call? Surely they will give update on dividend etc.
3 · Reply
LASTOCKS19
LASTOCKS19 Mar. 13 at 4:40 PM
$ABUS How about this before M&A deal, pre scheduled controlled 10b5-1 buyback is the most effective way for Roivant to maximize value for themselves and other controlled shareholders, given the small float, market cap, and cash inflow.
0 · Reply
MyBrokenBus
MyBrokenBus Mar. 13 at 2:29 PM
$ABUS after years of suppression on this perhaps the powers that be might try manipulating this thing, you know... up?
2 · Reply
rt_ch
rt_ch Mar. 13 at 1:57 PM
$ABUS Roiv made a deal with mrna
2 · Reply
mj6534
mj6534 Mar. 13 at 1:47 PM
$ABUS $ROIV really used us man. I knew I should’ve bought it at 3$. I’d be up 1000% instead only up a fraction of that
1 · Reply
User123321
User123321 Mar. 13 at 1:03 PM
$ABUS It’s Reno on a bender. At least it should stop his nonsensical posts for a few minutes. Kidding not kidding. At least this is in a buy area now but it certainly could go a bit lower.
0 · Reply
KellyKimberly
KellyKimberly Mar. 13 at 12:35 AM
$ABUS buy it if you want to get screwed twice
1 · Reply
SpaceCityKid
SpaceCityKid Mar. 13 at 12:02 AM
$ABUS The saga continues...
0 · Reply
Grtgooglymoogly
Grtgooglymoogly Mar. 12 at 11:47 PM
$ABUS Does anyone feel like being a contrarian optimist, and believe that the arbutus mngt. couldn't possibly be this quiet and this unCeo-like, that something else is about to unfold?....... Grasping.........
0 · Reply
hopeful2bright
hopeful2bright Mar. 12 at 11:01 PM
$ABUS Can’t wait for next CC and update on a plan, any plan, but must be a plan or what are we giving them stock options and salary for. HepB had exciting results and nothing?
0 · Reply
Onethousand1
Onethousand1 Mar. 12 at 8:58 PM
$ABUS What next?
1 · Reply
Thepatientone
Thepatientone Mar. 12 at 8:24 PM
$ABUS - We should demand a seat on the board as well. This management behaves like it should face no accountability. Does anyone know where the shareholders meeting will be held?
3 · Reply
NoBSPls
NoBSPls Mar. 12 at 7:29 PM
$ABUS “Arbuvant”
1 · Reply